Welcome to TripleBond
Catalogue No. CC0316
Product Name Crizotinib
CAS No. 877399-52-5
Purity 97%
Molecular Formula C21H22Cl2FN5O
Molecular Weight 450.34
Incki Key KTEIFNKAUNYNJU-GFCCVEGCSA-N
Quantity Price($)
1g 85.00 Place The Order
5g 245.00 Place The Order
Product Documents
No Product Documents


Description


Synonyms


  • PF 2341066
  • Xalkori


Crizotinib is a derivative of aminopyridine that acts as a potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases.1 Crizotinib shows antitumor efficacy, including cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM).1,2 Crizotinib is currently undergoing active clinical investigation in non-small cell lung cancer and phase I/II studies are being conducted in patients with anaplastic large cell lymphoma or neuroblastoma.2,3


Technical Information


Formal Name

3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

CAS Number

877399-52-5

Synonyms

  • PF 2341066
  • Xalkori

Formulation

A crystalline solid

λmax

206, 269, 323 nm

 

 


WARNING - This product is not for human or veterinary use.


Shipping & Storage


Storage

-20°C

Shipping

Room temperature in continental US; may vary elsewhere

Stability

As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly


References & Background Reading


Product Description References


1. Cui, J.J., Tran-Dubé, M., Shen, H., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54 6342-6363 (2011).


2. Tanizaki, J., Okamoto, I., Okamoto, K., et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6(10) 1624-1631 (2011).


3. Yuan, Y., Liao, Y., Hsueh, C., et al. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4(16) 1-14 (2011).


You May Also Like:


 


Contact Us
2-67 Watson Road South, Guelph Ontario, Canada N1L 1E3
info@triplebond-canada.com
Sales & Service: 1-855-880-0880 F: 1-855-880-0880
Also follow us on
© 2014 TripleBond Corporation. All Rights Reserved. Terms & Conditions